J
James M. Reuben
Researcher at University of Texas MD Anderson Cancer Center
Publications - 295
Citations - 21503
James M. Reuben is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 63, co-authored 286 publications receiving 19583 citations. Previous affiliations of James M. Reuben include Duke University & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Massimo Cristofanilli,Daniel F. Hayes,G. Thomas Budd,Mathew J. Ellis,A. Stopeck,James M. Reuben,Gerald V. Doyle,Jeri Matera,W. Jeffrey Allard,M. Craig Miller,Herbert A. Fritsche,Gabriel N. Hortobagyi,Leon W.M.M. Terstappen +12 more
TL;DR: In this article, the authors investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-free survival (PFS), and overall survival (OS) in patients with newly diagnosed metastatic breast cancer who were about to start first-line therapy.
Journal ArticleDOI
Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia
TL;DR: Alpha interferon appears to be highly effective in patients with hairy-cell leukemia with daily doses of 3 million units of partially pure alpha (leukocyte)interferon by the intramuscular route.
Journal ArticleDOI
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
Antoni Ribas,Luis H. Camacho,Gabriel Lopez-Berestein,Dmitri Pavlov,C. A. Bulanhagui,Robert Millham,Begoña Comin-Anduix,James M. Reuben,Elisabeth Seja,Charla A. Parker,Amarnath Sharma,John A. Glaspy,Jesus Gomez-Navarro +12 more
TL;DR: CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma.
Journal ArticleDOI
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Elise A. Olsen,Madeleine Duvic,Arthur E. Frankel,Youn H. Kim,Ann Martin,Eric C. Vonderheid,Brian V. Jegasothy,Gary S. Wood,Michael S. Gordon,Peter W. Heald,Allan Oseroff,Lauren C. Pinter-Brown,Glen Bowen,Timothy M. Kuzel,David P. Fivenson,Francine M. Foss,Michael Glode,Arturo Molina,Elizabeth Knobler,Stanford J. Stewart,Kevin D. Cooper,Seth R. Stevens,Fiona E. Craig,James M. Reuben,Patricia Bacha,Jean Nichols +25 more
TL;DR: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.